National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Republic of Singapore; Moorfields Eye Hospital and Biomedical Research Centre, Institute of Ophthalmology, University College London, London, United Kingdom; Singapore Eye Research Institute, Singapore, Republic of Singapore; School of Material Science and Engineering, Nanyang Technological University, Singapore, Republic of Singapore.
Moorfields Eye Hospital and Biomedical Research Centre, Institute of Ophthalmology, University College London, London, United Kingdom.
Ophthalmology. 2021 Feb;128(2):266-276. doi: 10.1016/j.ophtha.2020.01.008. Epub 2020 Jan 11.
An international, expert-led consensus initiative organized by the Collaborative Ocular Tuberculosis Study (COTS), along with the International Ocular Inflammation Society and the International Uveitis Study Group, systematically developed evidence- and experience-based recommendations for the treatment of tubercular choroiditis.
The diagnosis and management of tubercular uveitis (TBU) pose a significant challenge. Current guidelines and literature are insufficient to guide physicians regarding the initiation of antitubercular therapy (ATT) in patients with TBU.
An international expert steering subcommittee of the COTS group identified clinical questions and conducted a systematic review of the published literature on the use of ATT for tubercular choroiditis. Using an interactive online questionnaire, guided by background knowledge from published literature, 81 global experts (including ophthalmologists, pulmonologists, and infectious disease physicians) generated preliminary consensus statements for initiating ATT in tubercular choroiditis, using Oxford levels of medical evidence. In total, 162 statements were identified regarding when to initiate ATT in patients with tubercular serpiginous-like choroiditis, tuberculoma, and tubercular focal or multifocal choroiditis. The COTS group members met in November 2018 to refine these statements by a 2-step modified Delphi process.
Seventy consensus statements addressed the initiation of ATT in the 3 subtypes of tubercular choroiditis, and in addition, 10 consensus statements were developed regarding the use of adjunctive therapy in tubercular choroiditis. Experts agreed on initiating ATT in tubercular choroiditis in the presence of positive results for any 1 of the positive immunologic tests along with radiologic features suggestive of tuberculosis. For tubercular serpiginous-like choroiditis and tuberculoma, positive results from even 1 positive immunologic test were considered sufficient to recommend ATT, even if there were no radiologic features suggestive of tuberculosis.
Consensus guidelines were developed to guide the initiation of ATT in patients with tubercular choroiditis, based on the published literature, expert opinion, and practical experience, to bridge the gap between clinical need and available medical evidence.
由协作性眼结核研究组织(COTS)与国际眼炎症学会和国际葡萄膜炎研究小组共同领导的国际专家共识倡议,系统地制定了基于证据和经验的结核性脉络膜炎治疗推荐意见。
结核性葡萄膜炎(TBU)的诊断和管理极具挑战性。目前的指南和文献不足以指导医生在 TBU 患者中开始抗结核治疗(ATT)。
COTS 小组的一个国际专家指导小组委员会确定了临床问题,并对 ATT 治疗结核性脉络膜炎的已发表文献进行了系统回顾。使用由已发表文献中的背景知识指导的互动式在线问卷,81 名全球专家(包括眼科医生、肺病专家和传染病医生)针对结核性脉络膜炎开始 ATT 的时机生成了初步的共识声明,使用牛津医学证据水平。总共确定了 162 项关于何时开始 ATT 的声明,这些声明涉及结核性匐行性脉络膜炎、结核瘤和结核性局限性或多灶性脉络膜炎患者。2018 年 11 月,COTS 小组成员通过两步式修改德尔菲法来完善这些声明。
70 项共识声明涉及在 3 种结核性脉络膜炎亚型中开始 ATT 的问题,此外,还制定了 10 项关于结核性脉络膜炎辅助治疗的共识声明。专家们一致认为,在任何一种免疫测试阳性结果以及提示结核病的影像学特征的情况下,应开始 ATT 治疗结核性脉络膜炎。对于结核性匐行性脉络膜炎和结核瘤,即使只有一项免疫测试阳性结果也足以推荐 ATT,即使没有提示结核病的影像学特征。
根据已发表的文献、专家意见和实际经验,制定了共识指南,以指导结核性脉络膜炎患者 ATT 的开始,旨在弥合临床需求与现有医学证据之间的差距。